
Opinion|Videos|October 7, 2024
Introduction and Objectives to Advances in Targeted Therapy for Small Cell Lung Cancer
Author(s)Ticiana Leal, MD
Ticiana Leal, MD, discusses how recently approved targeted therapies for small cell lung cancer (SCLC) significantly enhance survival outcomes and reshape treatment strategies for both limited and extensive stages of the disease.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
1. Describe the case and your initial impressions:.
2. What would be the predominant goals of therapy for a patient such as this?
3. In patients with extensive stage SCLC small cell lung cancer (ES-SCLC)that has developed progression, how do you balance the survival benefits afforded by subsequent lines of therapy with risks of treatment-related adverse events after progression of disease on platinum-based primary therapy?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5






























